Compare abrdn Income Credit Strategies Fund (ACP) vs Zoetis Inc (ZTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Zoetis Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while Zoetis Inc trades at $75.18 (market cap $31.62B). The key difference: Zoetis Inc is far larger — about 48.2× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | ZTS | |
|---|---|---|
Market Cap | $656.21M | $31.62B |
Sector | Financials | Health |
52-Week High | $5.98 | $158.80 |
52-Week Low | $5.01 | $71.91 |
Dividend Yield | 17.78% | 2.81% |
Enterprise Value | — | $38.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
